Highly potent antiobesity effect of a short-length peptide YY analog in mice

Publication date: Available online 1 September 2017
Source:Bioorganic & Medicinal Chemistry
Author(s): Naoki Nishizawa, Ayumu Niida, Yusuke Adachi, Yoko Kanematsu-Yamaki, Yasushi Masuda, Satoshi Kumano, Kotaro Yokoyama, Yoko Noguchi, Tomoko Asakawa, Hideki Hirabayashi, Nobuyuki Amano, Shiro Takekawa, Tetsuya Ohtaki, Taiji Asami
Continuous administration of a 14-amino acid peptide YY (PYY) analog, Ac-[D-Pro²⁴,Pya(4)²⁶,Cha^27,36,Aib^28,31,Lys³⁰]PYY(23–36) (4), which has a high binding affinity and agonist activity for the neuropeptide Y2 receptor (Y2R), has previously shown an antiobesity effect in a 2-week diet-induced obesity (DIO) study in mice. However, there remained a possibility to obtain more potent analogs by further improving its pharmacokinetic profile. A combination of the N-terminal 4-imidazolecarbonyl moiety and three amino acid substitutions, trans-4-hydroxy-D-proline (D-Hyp)²⁴, isovaline (Iva)²⁵, and γ-methylleucine (γMeLeu)²⁸, not only improved the binding affinity of the peptide for Y2R but also increased its anorectic activity in lean mice. In a 2-week DIO study in mice, continuous administration of 4-imidazolecarbonyl-[D-Hyp²⁴,Iva²⁵,Pya(4)²⁶,Cha^27,36,γMeLeu²⁸,Lys³⁰,Aib³¹]PYY(23–36) (31, PYY-1119) at a dose of 0.03 mg/kg/day showed a highly potent antiobesity effect, with more than 10% body weight reduction.

Graphical abstract

http://ift.tt/2wZo66U